Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Lawrence, Tessa M ^a   Wanjalla, Celestine N ^a   Gomme, Emily A ^a   Wirblich, Christoph ^a   Gatt, Anthony ^a   Carnero, Elena ^b,d   García Sastre, Adolfo ^b   Lyles, Douglas S ^c   McGettigan, James P ^a   Schnell, Matthias J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR; RECOMBINANT DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INOCULATION; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PROTEIN EXPRESSION; RABIES VIRUS; RNA VIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; ANIMAL; BAGG ALBINO MOUSE; COMPARATIVE STUDY; GENE VECTOR; GENETICS; IMMUNOLOGY; PROCEDURES; SECONDARY IMMUNIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; NEWCASTLE DISEASE VIRUS; RABIES VIRUS; RNA VIRUSES; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DNA, RECOMBINANT; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV-1; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; RNA VIRUSES;

EID: 84879486184     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067123     Document Type: Article

References (52)

1. (2012) Estimated HIV incidence in the United States, 2007-2010. In: CDC, editor. HIV Surveillance Supplemental Report.
2. Fauci AS, (2003) HIV and AIDS: 20 years of science. Nat Med 9: 839-843.
3. Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, et al. (1999) Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 340: 1715-1722.
4. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, et al. (1999) Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 5: 194-203.
5. Fenner F, (1982) A successful eradication campaign. Global eradication of smallpox. Reviews of infectious diseases 4: 916-930.
6. Girard MP, Osmanov S, Assossou OM, Kieny MP, (2011) Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 29: 6191-6218.
7. Marthas ML, Sutjipto S, Higgins J, Lohman B, Torten J, et al. (1990) Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol 64: 3694-3700.
8. Liniger M, Zuniga A, Naim HY, (2007) Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6: 255-266.
9. Moore JP, Klasse PJ, Dolan MJ, Ahuja SK, (2008) AIDS/HIV. A STEP into darkness or light? Science 320: 753-755.
10. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, et al. (2012) Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 122: 359-367.
11. Schnell MJ, Mebatsion T, Conzelmann KK, (1994) Infectious rabies viruses from cloned cDNA. EMBO J 13: 4195-4203.
12. Lawson ND, Stillman EA, Whitt MA, Rose JK, (1995) Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 92: 4477-4481.
13. Nakaya T, Cros J, Park MS, Nakaya Y, Zheng H, et al. (2001) Recombinant Newcastle disease virus as a vaccine vector. J Virol 75: 11868-11873.
14. Mebatsion T, Schnell MJ, Cox JH, Finke S, Conzelmann KK, (1996) Highly stable expression of a foreign gene from rabies virus vectors. Proc Natl Acad Sci U S A 93: 7310-7314.
15. McGettigan JP, Naper K, Orenstein J, Koser M, McKenna PM, et al. (2003) Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. Journal of Virology 77: 10889-10899.
16. McGettigan JP, Koser ML, McKenna PM, Smith ME, Marvin JM, et al. (2006) Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology 344: 363-377.
17. Cooper D, Wright KJ, Calderon PC, Guo M, Nasar F, et al. (2008) Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 82: 207-219.
18. Carnero E, Li W, Borderia AV, Moltedo B, Moran T, et al. (2009) Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J Virol 83: 584-597.
19. Khattar SK, Samal S, Devico AL, Collins PL, Samal SK, (2011) Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. J Virol 85: 10529-10541.
20. McGettigan JP, Foley HD, Belyakov IM, Berzofsky JAYA, Pomerantz RJ, et al. (2001) Response against Envelope Proteins from Cross-Reactive Cytotoxic T-Lymphocyte (HIV-1) Envelope Protein Induce a Strong, Human Immunodeficiency Virus Type 1 Rabies Virus-Based Vectors Expressing Different HIV-1 Isolates. J Virol 75: 4430-4434.
21. Siler CA, McGettigan JP, Dietzschold B, Herrine SK, Dubuisson J, et al. (2002) Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292: 24-34.
22. Faber M, Lamirande EW, Roberts A, Rice AB, Koprowski H, et al. (2005) A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol 86: 1435-1440.
23. Tan GS, McKenna PM, Koser ML, McLinden R, Kim JH, et al. (2005) Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology 331: 82-93.
24. McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, et al. (2007) Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J Infect Dis 195: 980-988.
25. Faul EJ, Wanjalla CN, McGettigan JP, Schnell MJ, (2008) Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology 382: 226-238.
26. Faul EJ, Aye PP, Papaneri AB, Pahar B, McGettigan JP, et al. (2009) Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine 28: 299-308.
27. Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ, (2010) Characterization of a single-cycle rabies virus-based vaccine vector. J Virol 84: 2820-2831.
28. McGettigan JP, Foley HD, Belyakov IM, Berzofsky JA, Pomerantz RJ, et al. (2001) Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J Virol 75: 4430-4434.
29. Ahmed M, McKenzie MO, Puckett S, Hojnacki M, Poliquin L, et al. (2003) Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol 77: 4646-4657.
30. Ahmed M, Marino TR, Puckett S, Kock ND, Lyles DS, (2008) Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus. J Virol 82: 9273-9277.
31. Braxton CL, Puckett SH, Mizel SB, Lyles DS, (2010) Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J Virol 84: 3552-3561.
32. Gerlier D, Lyles DS (2011) Interplay between innate immunity and negative-strand RNA viruses: towards a rational model. Microbiol Mol Biol Rev 75: 468-490, second page of table of contents.
33. Ahmed M, Brzoza KL, Hiltbold EM, (2006) Matrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cells. J Virol 80: 2194-2205.
34. Ahmed M, Mitchell LM, Puckett S, Brzoza-Lewis KL, Lyles DS, et al. (2009) Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and-independent mechanisms. J Virol 83: 2962-2975.
35. Park MS, Garcia-Sastre A, Cros JF, Basler CF, Palese P, (2003) Newcastle disease virus V protein is a determinant of host range restriction. J Virol 77: 9522-9532.
36. Khattar SK, Yan Y, Panda A, Collins PL, Samal SK, (2009) A Y526Q mutation in the Newcastle disease virus HN protein reduces its functional activities and attenuates virus replication and pathogenicity. J Virol 83: 7779-7782.
37. Samal S, Kumar S, Khattar SK, Samal SK, (2011) A single amino acid change, Q114R, in the cleavage-site sequence of Newcastle disease virus fusion protein attenuates viral replication and pathogenicity. J Gen Virol 92: 2333-2338.
38. Kortekaas J, Antonis AF, Kant J, Vloet RP, Vogel A, et al. (2012) Efficacy of three candidate Rift Valley fever vaccines in sheep. Vaccine 30: 3423-3429.
39. Khattar SK, Collins PL, Samal SK, (2010) Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine 28: 3159-3170.
40. DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, et al. (2010) Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 84: 1489-1503.
41. Foley HD, McGettigan JP, Siler CA, Dietzschold B, Schnell MJ, (2000) A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc Natl Acad Sci U S A 97: 14680-14685.
42. McKenna PM, McGettigan JP, Pomerantz RJ, Dietzschold B, Schnell MJ, (2003) Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res 1: 229-237.
43. Kopecky SA, Willingham MC, Lyles DS, (2001) Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol 75: 12169-12181.
44. Wanjalla CN, Faul EJ, Gomme EA, Schnell MJ, (2010) Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. Vaccine 29: 130-140.
45. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB, (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68: 6103-6110.
46. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, et al. (1999) Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189: 991-998.
47. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
48. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
49. Faul EJ, Lyles DS, Schnell MJ, (2009) Interferon response and viral evasion by members of the family rhabdoviridae. Viruses 1: 832-851.
50. Qiu JT, Liu B, Tian C, Pavlakis GN, Yu XF, (2000) Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway. J Virol 74: 5997-6005.
51. zur Megede J, Chen MC, Doe B, Schaefer M, Greer CE, et al. (2000) Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 74: 2628-2635.
52. McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, et al. (2003) Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 77: 237-244.